Literature DB >> 8147353

Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea.

A Anand1, B Bashey, T Mir, A E Glatt.   

Abstract

OBJECTIVE: Clostridium difficile gastrointestinal disease is an important nosocomial infection and is associated with recent antibiotic use. This study evaluated C. difficile-associated diarrhea (CDAD) over a 2-yr period.
METHODS: All 60 patients with C. difficile enterotoxin in their stools, and diarrhea, were retrospectively analyzed at a 615-bed teaching hospital. Institution antibiotic usage and discharge medical diagnoses were correlated with the study patients.
RESULTS: Thirty-eight study patients (53%) had major or extreme admitting symptoms. Only four (7%) had no co-morbid illness. The incidence of CDAD increased significantly (p < 0.05) after 4 wk of hospitalization. No demographic or temporal clustering was discovered. Leukocytosis (60%), leftward polymorphonuclear shift (47%), dehydration (30%), weight loss (23%), and oliguria (12%) were the major clinical findings. Among these subject 51 (85%) had been on ceftriaxone and/or ceftazidime in the preceding 6 wk; ceftriaxone/ceftazidime was highly significantly associated (p < 0.01) with more cases than expected by usage alone. No patient on ticarcillin/clavulanate developed CDAD, although it was the most commonly used antibiotic (p < 0.00001). Higher mortality was associated with older debilitated nursing home residents.
CONCLUSIONS: Third-generation cephalosporin use correlated with the development of CDAD; ticarcillin/clavulanate usage did not. Morbidity and mortality associated with CDAD is significant, is worse in debilitated older nursing home patients, and is more likely to occur in hospitalizations lasting longer than 4 wk.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147353

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  Choosing the right antibiotic. Right drug at right time in right dose saves lives.

Authors:  D Bihari
Journal:  BMJ       Date:  1999-10-02

Review 2.  Clindamycin as an antimalarial drug: review of clinical trials.

Authors:  Bertrand Lell; Peter G Kremsner
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 3.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

4.  Clostridium difficile-associated diarrhea - the new scourge of the health care facility.

Authors:  J Conly
Journal:  Can J Infect Dis       Date:  2000-01

5.  Reactive arthritis to Clostridium difficile in a child.

Authors:  R Q Cron; P V Gordon
Journal:  West J Med       Date:  1997-06

6.  Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures.

Authors:  Gerard P Slobogean; Peter J O'Brien; Carmen A Brauer
Journal:  Acta Orthop       Date:  2010-04       Impact factor: 3.717

7.  Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.

Authors:  Xiao K Deng; Lance A Nesbit; K John Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 8.  Clostridium difficile Infection in Children: Current State and Unanswered Questions.

Authors:  Pranita D Tamma; Thomas J Sandora
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-25       Impact factor: 3.164

Review 9.  Clostridium difficile-associated diarrhea in adults.

Authors:  Susan M Poutanen; Andrew E Simor
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

10.  Pseudomembranous and neutropenic enterocolitis in pediatric oncology patients.

Authors:  M D van de Wetering; T W Kuijpers; J A J M Taminiau; F J W ten Kate; H N Caron
Journal:  Support Care Cancer       Date:  2003-05-24       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.